Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Iron chelation with deferasirox in a patient with de-novo ferroportin mutation.

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - 1 Apr 2015

Unal Sule, Piperno Alberto, Gumruk Fatma

Abstract excerpt

Ferroportin disease is a rare type of autosomal dominantly inherited hemochromatosis caused with mutations in the ferroportin gene (SLC40A1). The patients characteristically have hyperferritinemia but normal transferin saturations. Herein, we present a 15-year-old female whose chief complaint was persistent nausea for the last one year. Extensive work-up including brain imaging revealed nothing to explain the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Benzoates
Share to Cation Transport Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroportin

Share to Iron Chelating Agents

Share to Mutation

Share to Triazoles

Source

Identifiers

PMID: 25744502
DOI: 10.1016/j.jtemb.2015.01.002

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Iron chelation with deferasirox in a patient with de-novo ferroportin mutation.PMID 25744502Read ↗

Ferroportin disease: pathogenesis, diagnosis and treatment.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Effectiveness of oral iron chelator treatment with deferasirox in an aceruloplasminemia patient with a novel ceruloplasmin gene mutation.Semantic proximity Read ↗

Iron overload due to SLC40A1 mutation of type 4 hereditary hemochromatosis.Semantic proximity Read ↗

Ferroportin Disease Caused by a Heterozygous Variant p.Cys326Phe in the SLC40A1 Gene and the Efficacy of Therapeutic Phlebotomy in Children.Semantic proximity Read ↗

Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report.Semantic proximity Read ↗

Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.Semantic proximity Read ↗

Non-invasive diagnosis and follow-up of hyperferritinaemia.Semantic proximity Read ↗

Genetic and clinical heterogeneity of ferroportin disease.Semantic proximity Read ↗

Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.Semantic proximity Read ↗

Response to Prolonged Duration of Therapeutic Dose Oral Iron Therapy in a Girl With Novel TMPRSS6 Gene Variants: A Case Report and Review Literature.Semantic proximity Read ↗

Diagnosing Aceruloplasminemia: Navigating through Red HerringsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.